InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
- INF904, an orally available C5aR inhibitor, showed positive results in the Phase I trial. It was well tolerated and achieved effective C5aR control at disease relevant C5a levels.
- Phase III trial of vilobelimab for the treatment of pyoderma gangrenosum has been initiated, with the first patients being screened. The trial has an adaptive design and will assess the complete closure of the target ulcer as the primary endpoint.
- A Marketing Authorization Application (MAA) for vilobelimab for the treatment of SARS-CoV-2 induced septic ARDS in critically ill COVID-19 patients has been submitted and validated by the European Medicines Agency (EMA).
- Development of vilobelimab in cutaneous squamous cell carcinoma (cSCC) has been stopped to prioritize other programs. The decision was made due to the emergence of new alternative treatments for cSCC and the need for substantial resources to study additional patients.
- The interim analysis of the Phase II study of vilobelimab in cSCC showed encouraging efficacy signals, with two partial responses observed. However, the study will not proceed to the second stage.
- No financial negatives were mentioned in the press release.
- Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoing
- Six clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG)
- FDA regulatory pathway towards BLA in broader acute respiratory distress syndrome (ARDS) indication discussed in encouraging FDA Type C meeting
- MAA for vilobelimab for treatment of SARS-CoV-2 induced septic ARDS in critically ill COVID-19 patients submitted and validated by EMA
- Update on development of vilobelimab in cutaneous squamous cell carcinoma (cSCC)
- First commercial sales for Gohibic (vilobelimab) recorded in the third quarter 2023
- Cash, cash equivalents and marketable securities of
€113 million , expected to fund operations at least into 2026
JENA, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financial results for the three and nine months ended September 30, 2023, and provided an operating update.
“In recent months, we have made exciting progress with both vilobelimab and our small molecule C5aR inhibitor INF904. With the commercial launch of Gohibic (vilobelimab) in the United States now underway, we are also advancing vilobelimab in pyoderma gangrenosum, recently initiating a Phase III trial in this debilitating skin disease,” said Prof. Niels C. Riedemann, Chief Executive Officer and Co-founder of InflaRx.
He continued: “With INF904, we set out to develop an orally bioavailable inhibitor of C5a signaling with best-in-class potential, and the initial data from our Phase I trial strongly support this. We look forward to seeing additional data from this ongoing study with this promising treatment candidate. Ultimately, we are planning to develop INF904 in a chronic inflammatory condition and dedicate more resources towards this exciting new development going forward.”
Recent Highlights and Business Update
INF904 – Positive Topline Results from Single Ascending Dose (SAD) Part of Phase I Trial Support Best-in-Class Potential as Orally Administered C5aR Inhibitor
InflaRx recently announced positive topline results from the SAD part of a randomized, double-blind, placebo-controlled Phase I trial in healthy volunteers to assess the safety, tolerability and pharmacokinetic / pharmacodynamic (PK/PD) properties of InflaRx’s low molecular weight C5aR inhibitor INF904.
The results showed that INF904 was well tolerated and resulted in no safety signals of concern in single doses ranging from 3 mg to 240 mg. Analysis of INF904 in subject plasma samples revealed a favorable PK profile that, at the 30 mg dose and above, surpassed the values for systemic exposure (AUClast) and maximum concentration (Cmax) of published Phase I data from the only marketed comparator. Further, ex vivo assays showed that INF904 achieved the set goal for effective C5aR control at disease relevant C5a levels.
The multiple ascending dose (MAD) part of the Phase 1 trial is ongoing, and the Company expects to present results from the approximately 24 healthy volunteers enrolled in this part of the study at the beginning of 2024. InflaRx is currently preparing to initiate additional required pre-clinical studies, including chronic toxicology studies, for the future clinical development of INF904 in chronic inflammatory diseases. In parallel, the Company is evaluating selected potential indications for future development.
Development of Vilobelimab in Pyoderma Gangrenosum (PG):
InflaRx is well underway in a pivotal Phase III study with vilobelimab for the treatment of ulcerative PG. As of today, InflaRx has initiated the first six clinical sites in the United States and is actively screening patients. The Company foresees being able to start treating the first patient very soon. The multi-national, randomized, double-blind, placebo-controlled trial has two arms: vilobelimab (2400mg every other week) plus a low dose of corticosteroids and placebo plus the same low dose of corticosteroids. The primary endpoint of the study is complete closure of the target ulcer at any time up to 26 weeks after initiation of treatment.
The study has an adaptive trial design with an interim analysis blinded for the sponsor and investigators planned upon enrollment of approximately 30 patients (15 per arm). Depending on the results of the interim analysis, the trial sample size will be adapted, or the trial will be stopped due to futility. The enrollment period is projected to be at least two years, depending on the total trial size after sample size adaptation.
Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
This summer, the Company submitted an MAA for the treatment of adult patients with SARS-CoV-2 induced septic acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) to the EMA. The EMA has validated the MAA, which means that the application is now under regulatory review by the European Committee for Medicinal Products for Human Use (CHMP) under the centralized procedure, which applies to all 27 member states of the European Union.
Commercial Launch of Gohibic (vilobelimab) for the Treatment of Critically Ill COVID-19 Patients following Emergency Use Authorization (EUA) in the United States:
In April 2023, the U.S. Food and Drug Administration (FDA) issued an EUA for Gohibic (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving IMV or ECMO. Gohibic (vilobelimab) has been commercially available to hospitals across the United States since late Q2 and initial sales were made in Q3.
InflaRx is currently developing its commercial strategic plan and seeking to increase awareness of Gohibic (vilobelimab). In parallel, the Company is also exploring paths to gain full market approval via a biologics license application (BLA) in the United States. In October 2023, InflaRx held an encouraging Type C meeting with the FDA related to additional steps towards a BLA. The FDA indicated that FDA is committed to working with InflaRx to address challenges and expedite development of vilobelimab as a treatment for ARDS. In order to obtain a BLA for ARDS, the Company would need to conduct an additional well-controlled and adequately powered study in a broader ARDS setting. InflaRx is exploring different funding options, including government grants as well as collaborations with third parties.
InflaRx Stops Development of Vilobelimab in Cutaneous Squamous Cell Carcinoma (cSCC) to Prioritize Other Programs
InflaRx is conducting an open-label, multicenter Phase II study, evaluating vilobelimab in two study arms - as a monotherapy (Arm A) and in combination with pembrolizumab (Arm B) - in patients with programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitor in resistant/refractory, locally advanced or metastatic cSCC. The main objectives of this trial are to assess the safety and antitumor activity of vilobelimab in the monotherapy arm and to assess the maximum tolerated or recommended dose of vilobelimab and the safety and antitumor activity of this drug pair in the combination arm.
An interim analysis of ten evaluable patients in the monotherapy Arm A showed first evaluable signals of efficacy. In Arm B, 15 patients were enrolled (3+6+6 in three dosing cohorts). Before proceeding with the second stage of the study in Arm B, the interim efficacy data were assessed and showed two partial responses - one patient in the second cohort and one patient in the third cohort. Both patients are still on treatment.
While these results are encouraging, the recent emergence of new alternative treatments for cSCC and the recommendation by the Company’s U.S. and international experts to study additional patients with a higher dose of vilobelimab as monotherapy would require substantial resources and significantly extend the timelines of the ongoing clinical program. InflaRx has therefore decided to stop development in cSCC for the time being and reallocate resources towards the development of the promising orally available C5aR inhibitor, INF904.
Patients who are currently still in treatment will be treated for up to 24 months according to the protocol; however, no new patients will be enrolled in the study and clinical sites in which no patients are currently being treated will be closed down. The decision to wind down this clinical study does not preclude InflaRx from developing vilobelimab or INF904 in cSCC or similar oncology indications in the future.
Financing Activities
In October 2021, InflaRx announced the receipt of a grant of up to
Dr. Thomas Taapken, Chief Financial Officer of InflaRx, said: “This quarter was the first time that InflaRx has recorded sales revenues, an achievement that very few biotech companies reach. We are further expanding our commercial activities over the coming months as cases of severe COVID-19 are anticipated to increase over the winter months. Our company is funded to support operations well into 2026, which is important in the continued challenging financial market environment.”
Financial Highlights – Q3 2023
Revenue
In Q3 2023, the Company realized revenues from product sales for the first time since its inception. Revenues reported are actual sales to end customers (hospitals). Sales to distributors, of which
Cost of Sales
Cost of sales recognized during the nine months ended September 30, 2023, are related to Gohibic (vilobelimab) revenues in the United States. Costs of sales for products sold in this period do not include costs of materials, as the associated costs of these materials were incurred in prior periods, before granting of an EUA for Gohibic (vilobelimab). These materials were recorded as research and development expenses in the period they were incurred.
Cost of sales during the first nine months of 2023 mainly consisted of write-downs of inventories that will expire prior to their expected sale. Early product batches, capitalized in inventory, were produced with material which had been manufactured in previous years. The inventory write-down for the nine months ended September 30, 2023, amounted to
Sales and Marketing Expenses
In the nine months ended September 30, 2023, InflaRx incurred
Research and Development Expenses
Research and development expenses incurred for the nine months ended September 30, 2023, increased by
General and Administrative Expenses
General and administrative expenses decreased by
Other Income
Other income decreased by
Net Financial Result
Net financial result increased by
Net Loss
Net loss for the first nine months of 2023 amounted to
Net Cash Used in Operating Activities
Net cash used in operating activities for the first nine months of 2023 decreased to
Liquidity and Capital Resources
As of September 30, 2023, the Company’s total available funds were approximately
Additional Financial Information
Additional information regarding these results and other relevant information is included in the notes to the unaudited interim condensed consolidated financial statements as of September 30, 2023, and the three and nine months ended September 30, 2023, and 2022, as well as the consolidated financial statements as of and for the year ended December 31, 2022, in “ITEM 18. Financial Statements,” in InflaRx’s Annual Report on Form 20-F for the year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission (SEC).
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022
| For the three months ended September 30, | For the nine months ended September 30 | |||||||
| 2023 (unaudited) | 2022 (unaudited) | 2023 (unaudited) | 2022 (unaudited) | |||||
| (in €, except for share data) | ||||||||
| Revenues | 60,803 | — | 60,803 | — | ||||
| Cost of Sales | (255,116) | — | (255,116) | — | ||||
| Gross profit | (194,313) | — | (194,313) | — | ||||
| Sales and marketing expenses | (1,562,473) | — | (1,838,524) | — | ||||
| Research and development expenses | (7,305,541) | (7,537,350) | (32,957,044) | (29,190,231) | ||||
| General and administrative expenses | (2,897,732) | (3,087,285) | (10,047,091) | (11,821,694) | ||||
| Other income | 808,866 | 2,030,406 | 13,437,963 | 16,473,540 | ||||
| Other expenses | 339 | — | (2,851) | (844) | ||||
| Operating Result | (11,150,854) | (8,594,230) | (31,601,861) | (24,539,229) | ||||
| Finance income | 1,189,826 | 199,758 | 2,732,873 | 310,121 | ||||
| Finance expenses | (4,897) | (6,845) | (15,476) | (39,376) | ||||
| Foreign exchange result | 2,292,938 | 882,370 | 1,923,274 | 3,173,883 | ||||
| Other financial result | 221,577 | (402,724) | 223,818 | (363,724) | ||||
| Income Taxes | — | — | — | — | ||||
| Income (Loss) for the Period | (7,451,410) | (7,921,671) | (26,737,373) | (21,458,325) | ||||
| Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods: | ||||||||
| Exchange differences on translation of foreign currency | 73,574 | 4,317,134 | 56,459 | 10,035,949 | ||||
| Total Comprehensive Income (Loss) | (7,377,836) | (3,604,538) | (26,680,914) | (11,422,376) | ||||
| Share Information (based on Income (Loss) for the Period) | ||||||||
| Weighted average number of shares outstanding | 58,883,272 | 44,203,763 | 53,598,594 | 44,203,763 | ||||
| Income (Loss) per share (basic/diluted) | (0.13) | (0.18) | (0.50) | (0.49) | ||||
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Financial Position as of September 30, 2023 and December 31, 2022
| September 30, 2023 (unaudited) | December 31, 2022 | |||
| (in €) | ||||
| ASSETS | ||||
| Non-current assets | ||||
| Property and equipment | 298,344 | 328,920 | ||
| Right-of-use assets | 1,076,402 | 1,311,809 | ||
| Intangible assets | 66,734 | 138,905 | ||
| Other assets | 270,526 | 308,066 | ||
| Financial assets | 237,564 | 2,900,902 | ||
| Total non-current assets | 1,949,570 | 4,988,602 | ||
| Current assets | ||||
| Inventories | 1,639,490 | — | ||
| Current other assets | 7,779,994 | 14,170,510 | ||
| Current tax assets | 3,398,481 | 1,432,087 | ||
| Financial assets from government grants | 1,164,217 | 732,971 | ||
| Other financial assets | 91,857,945 | 64,810,135 | ||
| Cash and cash equivalents | 21,695,607 | 16,265,355 | ||
| Total current assets | 127,535,734 | 97,411,058 | ||
| TOTAL ASSETS | 129,485,304 | 102,399,660 | ||
| EQUITY AND LIABILITIES | ||||
| Equity | ||||
| Issued capital | 7,065,993 | 5,364,452 | ||
| Share premium | 334,211,338 | 282,552,633 | ||
| Other capital reserves | 39,597,055 | 36,635,564 | ||
| Accumulated deficit | (270,197,663) | (243,460,290) | ||
| Other components of equity | 7,313,540 | 7,257,081 | ||
| Total equity | 117,990,262 | 88,349,440 | ||
| Non-current liabilities | ||||
| Lease liabilities | 771,814 | 987,307 | ||
| Other liabilities | 36,877 | 36,877 | ||
| Total non-current liabilities | 808,691 | 1,024,184 | ||
| Current liabilities | ||||
| Trade and other payables | 5,999,200 | 4,987,538 | ||
| Liabilities from government grants | — | 6,209,266 | ||
| Lease liabilities | 354,151 | 369,376 | ||
| Employee benefits | 1,285,355 | 1,312,248 | ||
| Other liabilities | 3,047,646 | 147,608 | ||
| Total current liabilities | 10,686,351 | 13,026,036 | ||
| Total Liabilities | 11,495,042 | 14,050,220 | ||
| TOTAL EQUITY AND LIABILITIES | 129,485,304 | 102,399,660 | ||
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity for the nine months ended September 30, 2023 and 2022
| (in €) | Issued capital | Share premium | Other capital reserves | Accumulated deficit | Other components of equity | Total equity | ||||||
| Balance as of January 1, 2023 | 5,364,452 | 282,552,633 | 36,635,564 | (243,460,290) | 7,257,081 | 88,349,440 | ||||||
| Loss for the period | — | — | — | (26,737,373) | — | (26,737,373) | ||||||
| Exchange differences on translation of foreign currency | — | — | — | — | 56,459 | 56,459 | ||||||
| Total comprehensive loss | — | — | — | (26,737,373) | 56,459 | (26,680,914) | ||||||
| Issuance of common shares | 1,687,110 | 54,796,819 | — | — | — | 56,483,929 | ||||||
| Transaction costs | — | (3,360,626) | — | — | — | (3,360,626) | ||||||
| Equity-settled share-based payments | — | — | 2,961,491 | — | — | 2,961,491 | ||||||
| Share options exercised | 14,431 | 222,512 | — | — | — | 236,943 | ||||||
| Balance as of September 30, 2023 | 7,065,993 | 334,211,338 | 39,597,055 | (270,197,663) | 7,313,540 | 117,990,262 | ||||||
| Balance as of January 1, 2022 | 5,304,452 | 280,310,744 | 30,591,209 | (213,975,679) | 3,050,271 | 105,280,996 | ||||||
| Loss for the period | — | — | — | (21,458,325) | — | (21,458,325) | ||||||
| Exchange differences on translation of foreign currency | — | — | — | — | 10,035,949 | 10,035,949 | ||||||
| Total comprehensive loss | — | — | — | (21,458,325) | 10,035,949 | (11,422,376) | ||||||
| Equity-settled share-based payments | — | — | 5,581,021 | — | — | 5,581,021 | ||||||
| Balance as of September 30, 2022 | 5,304,452 | 280,310,744 | 36,172,229 | (235,434,004) | 13,086,220 | 99,439,640 | ||||||
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022
| For the nine months ended September 30, | ||||
| 2023 (unaudited) | 2022 (unaudited) | |||
| (in €) | ||||
| Operating activities | ||||
| Loss for the period | (26,737,373) | (21,458,325) | ||
| Adjustments for: | ||||
| Depreciation & amortization of property and equipment, right-of-use assets and intangible assets | 432,248 | 448,323 | ||
| Net finance income | (4,864,488) | (3,080,904) | ||
| Share-based payment expense | 2,961,491 | 5,581,021 | ||
| Net foreign exchange differences | (82,574) | 189,088 | ||
| Changes in: | ||||
| Financial assets from government grants | (431,246) | (5,954,754) | ||
| Other assets | 4,468,239 | 3,087,177 | ||
| Employee benefits | (26,893) | (221,982) | ||
| Other liabilities | 2,893,461 | 5,061 | ||
| Liabilities from government grants received | (6,209,266) | (6,849,415) | ||
| Trade and other payables | 1,011,662 | (1,135,817) | ||
| Inventories | (1,639,490) | — | ||
| Interest received | 1,302,391 | 903,647 | ||
| Interest paid | (15,773) | (38,978) | ||
| Net cash used in operating activities | (26,937,611) | (28,525,857) | ||
| Investing activities | ||||
| Purchase of intangible assets, property and equipment | (45,942) | (17,908) | ||
| Purchase of current financial assets | (91,590,134) | (47,031,216) | ||
| Proceeds from the maturity of financial assets | 71,113,455 | 64,600,049 | ||
| Net cash from/(used in) investing activities | (20,522,621) | 17,550,925 | ||
| Financing activities | ||||
| Proceeds from issuance of common shares | 56,483,929 | — | ||
| Transaction costs from issuance of common shares | (3,360,626) | — | ||
| Proceeds from exercise of share options | 236,943 | — | ||
| Repayment of lease liabilities | (279,075) | (273,092) | ||
| Net cash from/(used in) financing activities | 53,081,170 | (273,092) | ||
| Net increase/(decrease) in cash and cash equivalents | 5,620,938 | (11,248,024) | ||
| Effect of exchange rate changes on cash and cash equivalents | (190,686) | 2,976,033 | ||
| Cash and cash equivalents at beginning of period | 16,265,355 | 26,249,995 | ||
| Cash and cash equivalents at end of period | 21,695,607 | 17,978,003 | ||
About InflaRx
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
InflaRx (Nasdaq: IFRX) is a biotechnology company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize first-in-class, potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
The COVID-19 related work described herein is partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx.
Contacts:
InflaRx N.V.
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals and related treatment recommendations by medical/healthcare institutes and other third-party organizations, our ability to successfully commercialize and the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals or our other product candidates; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of Gohibic (vilobelimab) in its approved or authorized indication or for vilobelimab and any other product candidates, under an EUA and in the future if approved for commercial use in the United States or elsewhere; the success of our future clinical trials for vilobelimab and any other product candidates and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; the timing, progress and results of pre-clinical studies and clinical trials of our product candidates, including the MAD part of the Phase 1 trial with C5aR inhibitor INF904, and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including related to our MAA submission for vilobelimab and our BLA submission for Gohibic (vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or Gohibic (vilobelimab) for any indication; whether the FDA, the EMA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our expectations regarding the scope of any approved indication for vilobelimab; our ability to leverage our proprietary anti-C5a and C5aR technologies to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab and for the finished product Gohibic (vilobelimab); our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates obtain regulatory approval, our ability to comply with and satisfy ongoing obligations and continued regulatory overview; our ability to comply with enacted and future legislation in seeking marketing approval and commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
What is the status of INF904?
What is the status of the Phase III trial for vilobelimab?
What is the status of the Marketing Authorization Application (MAA) for vilobelimab?
Why was the development of vilobelimab in cutaneous squamous cell carcinoma (cSCC) stopped?
What were the results of the Phase II study of vilobelimab in cSCC?
What is the financial status of InflaRx?
